OliX Pharmaceuticals Inc. announced the completion of patient enrollment in the Phase 2a clinical trial of OLX101A, an investigational therapeutic program for the treatment of hypertrophic scar. In October 2020, the Company received FDA clearance to advance the investigation of OLX10010 (compound name of OLX101A) and began enrolling patients for the Phase 2a clinical trial across five sites in the U.S. The study is conducted to determine the efficacy of OLX10010 in reducing the recurrence of hypertrophic scars after scar revision surgery. A hypertrophic scar is a thick, wide, and raised scar that results from an overgrowth of collagen in the dermis.

It is a common abnormal response during the wound healing process and occurs in 40% to 70% of patients following surgery. Effective treatments for these patients remain elusive to date. Specifically, there are no FDA-approved drugs that treat the root cause of hypertrophic scars, which leaves a high unmet medical need for the treatment.

According to Grand View Research, the global market for hypertrophic and keloid scars is expected to grow from USD 7.6 billion in 2022 to USD 14.6 billion in 2030.